Morgan Stanley Ventyx Biosciences, Inc. Transaction History

Morgan Stanley

$1.23 Trillion
Q1 2024

A detailed history of Morgan Stanley transactions in Ventyx Biosciences, Inc. stock. As of the latest transaction made, Morgan Stanley holds 1,334,338 shares of VTYX stock, worth $6.38 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,334,338

Previous 1,915,026 30.32%

Holding current value

$6.38 Million

Previous $4.73 Million 55.14%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$1.9 - $10.13 $1.1 Million - $5.88 Million	-580,688 Reduced 30.32%	1,334,338 $7.34 Million
Q4 2023 Feb 13, 2024	BUY	$2.08 - $31.18 $3.39 Million - $50.9 Million	1,630,919 Added 574.05%	1,915,026 $4.73 Million
Q3 2023 Nov 15, 2023	SELL	$29.8 - $40.3 $6.86 Million - $9.28 Million	-230,184 Reduced 44.76%	284,107 $9.87 Million
Q2 2023 Aug 14, 2023	SELL	$28.53 - $39.55 $2.33 Million - $3.23 Million	-81,585 Reduced 13.69%	514,291 $16.9 Million
Q1 2023 May 15, 2023	BUY	$29.51 - $46.65 $14.1 Million - $22.2 Million	476,662 Added 399.84%	595,876 $20 Million

Q4 2022 Feb 14, 2023	BUY	$24.16 - $36.38 $880,607 - $1.33 Million	36,449 Added 44.04%	119,214 $3.91 Million
Q3 2022 Nov 14, 2022	BUY	$12.64 - $38.7 $802,791 - $2.46 Million	63,512 Added 329.88%	82,765 $2.89 Million
Q2 2022 Oct 27, 2022	BUY	$11.95 - $18.75 $149,805 - $235,050	12,536 Added 186.63%	19,253 $236,000
Q2 2022 Aug 15, 2022	BUY	$11.95 - $18.75 $149,805 - $235,050	12,536 Added 186.63%	19,253 $236,000
Q1 2022 Oct 27, 2022	SELL	$10.0 - $19.98 $125,360 - $250,469	-12,536 Reduced 65.11%	6,717 $91,000
Q1 2022 May 13, 2022	SELL	$10.0 - $19.98 $690 - $1,378	-69 Reduced 1.02%	6,717 $91,000
Q4 2021 Feb 14, 2022	BUY	$14.2 - $23.07 $96,361 - $156,553	6,786 New	6,786 $135,000

Others Institutions Holding VTYX

# of Institutions

134

Shares Held

59.2M

Call Options Held

180K

Put Options Held

179K

View Full List

About Ventyx Biosciences, Inc.

Ticker VTYX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,527,200
Market Cap $270M
Description
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...

More about VTYX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account